{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T15:26:27Z","timestamp":1773329187653,"version":"3.50.1"},"reference-count":26,"publisher":"Cambridge University Press (CUP)","issue":"6","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Can. J. Neurol. Sci."],"published-print":{"date-parts":[[2019,11]]},"abstract":"<jats:title>ABSTRACT:<\/jats:title><jats:sec id=\"S0317167119002385_as1\"><jats:title>Background:<\/jats:title><jats:p>Although therapeutic treatments are intended to help alleviate symptoms associated with disease, safety must be carefully considered and monitored to confirm continued positive benefit\/risk balance. The objective of MOBILITY was to study the long-term safety of onabotulinumtoxinA for treatment of various therapeutic indications.<\/jats:p><\/jats:sec><jats:sec id=\"S0317167119002385_as2\"><jats:title>Methods:<\/jats:title><jats:p>A prospective, multicenter, observational, Phase IV Canadian study in patients treated with onabotulinumtoxinA for a therapeutic indication. Dosing was determined by the participating physician. Adverse events (AEs) were recorded throughout the study.<\/jats:p><\/jats:sec><jats:sec id=\"S0317167119002385_as3\"><jats:title>Results:<\/jats:title><jats:p>Patients (<jats:italic>n<\/jats:italic>= 1372) with adult focal spasticity, blepharospasm, cerebral palsy, cervical dystonia, hemifacial spasm, hyperhidrosis, or \u201cother\u201d diagnoses were enrolled into the safety cohort. Eighty-three patients (6%) reported 209 AEs; 44 AEs in 24 patients (2%) were considered treatment-related AEs. Seventy-two serious AEs were reported by 38 patients (3%); 10 serious AEs in 5 patients (0.4%) were considered treatment related. Most commonly reported treatment-related AEs were muscular weakness (<jats:italic>n<\/jats:italic>= 7\/44) and dysphagia (<jats:italic>n<\/jats:italic>= 6\/44).<\/jats:p><\/jats:sec><jats:sec id=\"S0317167119002385_as4\"><jats:title>Conclusions:<\/jats:title><jats:p>In patients with follow-up for up to six treatments with onabotulinumtoxinA, treatment-related AEs were reported in &lt;2% of the safety population over the course of nearly 5 years. Our findings from MOBILITY provide further evidence that onabotulinumtoxinA treatment is safe for long-term use across a variety of therapeutic indications.<\/jats:p><\/jats:sec>","DOI":"10.1017\/cjn.2019.238","type":"journal-article","created":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T06:51:10Z","timestamp":1561963870000},"page":"742-752","source":"Crossref","is-referenced-by-count":3,"title":["Long-term Safety and Dosing of OnabotulinumtoxinA: A Prospective, Observational Study"],"prefix":"10.1017","volume":"46","author":[{"given":"Theodore","family":"Wein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mandar","family":"Jog","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meetu","family":"Bhogal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonja","family":"Dhani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farooq","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Beauchamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace","family":"Trentin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2019,7,1]]},"reference":[{"key":"S0317167119002385_ref23","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2002.49101.x"},{"key":"S0317167119002385_ref20","doi-asserted-by":"publisher","DOI":"10.1177\/0269215511412799"},{"key":"S0317167119002385_ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2011.06.013"},{"key":"S0317167119002385_ref3","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27072"},{"key":"S0317167119002385_ref8","volume-title":"Clostridium botulinum type A neurotoxin complex). Full prescribing information.","year":"2016"},{"key":"S0317167119002385_ref5","doi-asserted-by":"publisher","DOI":"10.1177\/0333102414527648"},{"key":"S0317167119002385_ref2","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1128\/MR.56.1.80-99.1992","article-title":"Properties and use of botulinum toxin and other microbial neurotoxins in medicine","volume":"56","author":"Schantz","year":"1992","journal-title":"Microbiol Rev"},{"key":"S0317167119002385_ref7","volume-title":"Product monograph. Summary of product characteristics.","year":"2016"},{"key":"S0317167119002385_ref24","volume-title":"Summary of product characteristics","year":"2014"},{"key":"S0317167119002385_ref1","doi-asserted-by":"publisher","DOI":"10.2174\/0929867043363802"},{"key":"S0317167119002385_ref25","first-page":"1","article-title":"Botulinum toxin type A (Botox) and distant toxin spread","volume":"2016","year":"2008","journal-title":"Canadian Adverse Reaction Newsletter"},{"key":"S0317167119002385_ref13","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.162.20.2269"},{"key":"S0317167119002385_ref15","doi-asserted-by":"publisher","DOI":"10.1097\/00002060-200007000-00010"},{"key":"S0317167119002385_ref14","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.59.3.418"},{"key":"S0317167119002385_ref11","doi-asserted-by":"publisher","DOI":"10.1177\/0269215508099860"},{"key":"S0317167119002385_ref26","unstructured":"26. US Food and Drug Administration. OnabotulinumtoxinA (marketed as Botox\/Botox Cosmetic), abobotulinumtoxinA (marketed as Dysport) and rimabotulinumtoxinB (marketed as Myobloc) information. Available at: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm175011.htm. accessed December 13, 2017."},{"key":"S0317167119002385_ref17","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2006-2425"},{"key":"S0317167119002385_ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2014.07.046"},{"key":"S0317167119002385_ref19","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2012-000881"},{"key":"S0317167119002385_ref16","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20376"},{"key":"S0317167119002385_ref10","volume-title":"MedDRA Version 15.1","year":"2012"},{"key":"S0317167119002385_ref21","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.62.2.198"},{"key":"S0317167119002385_ref22","first-page":"163","article-title":"Botulism-like syndrome after injections of botulinum toxin","volume":"42","author":"Cobb","year":"2000","journal-title":"Vet Hum Toxicol"},{"key":"S0317167119002385_ref12","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.4.2.241"},{"key":"S0317167119002385_ref18","doi-asserted-by":"publisher","DOI":"10.1177\/0333102414544974"},{"key":"S0317167119002385_ref6","volume-title":"Clostridium botulinum type A neurotoxin complex (900kD) Sterile vacuum-dried concentrate powder for solution for injection 50, 100 and 200 Allergan units per vial","year":"2016"}],"container-title":["Canadian Journal of Neurological Sciences \/ Journal Canadien des Sciences Neurologiques"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0317167119002385","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T19:52:54Z","timestamp":1610135574000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0317167119002385\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,1]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0317167119002385"],"URL":"https:\/\/doi.org\/10.1017\/cjn.2019.238","relation":{},"ISSN":["0317-1671","2057-0155"],"issn-type":[{"value":"0317-1671","type":"print"},{"value":"2057-0155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,1]]}}}